Isoprenoid modification permits 2',3'-cyclic nucleotide 3'-phosphodiesterase to bind to membranes

J Neurosci Res. 1991 Nov;30(3):540-4. doi: 10.1002/jnr.490300311.

Abstract

The myelination-related enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), a relatively abundant protein in the CNS possesses the C-terminal isoprenylation consensus domain found in a small family that includes the ras oncoproteins and their relatives, some G-proteins, and nuclear lamins. We found that CNP, like these other proteins, is modified posttranslationally by an isoprenoid derived from mevalonic acid. It appears that only the smaller of the two CNP isoforms (CNP1) is isoprenylated, but similar modification of CNP2 cannot be excluded. Inhibition of isoprenoid synthesis by Lovastatin blocks the binding of newly synthesized CNP to cell membranes; binding is restored upon addition of mevalonate to the culture medium. This shows that isoprenylation is permissive for the well-known avid association of CNP with membranes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2',3'-Cyclic-Nucleotide Phosphodiesterases / genetics
  • 2',3'-Cyclic-Nucleotide Phosphodiesterases / isolation & purification
  • 2',3'-Cyclic-Nucleotide Phosphodiesterases / metabolism*
  • Amino Acid Sequence
  • Animals
  • Cell Line
  • Cell Membrane / enzymology
  • Cytosol / enzymology
  • Glioma
  • Lovastatin / pharmacology
  • Mevalonic Acid / analogs & derivatives*
  • Mevalonic Acid / metabolism
  • Molecular Sequence Data
  • Molecular Weight
  • Protein Binding
  • Protein Processing, Post-Translational*

Substances

  • mevalonolactone
  • Lovastatin
  • 2',3'-Cyclic-Nucleotide Phosphodiesterases
  • Mevalonic Acid